- Home
- DSGN vs RCS Comparison
DSGN vs RCS Comparison
Compare DSGN & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- RCS
- Stock Information
- Founded
- DSGN 2017
- RCS 1994
- Country
- DSGN United States
- RCS United States
- Employees
- DSGN N/A
- RCS N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- DSGN Health Care
- RCS Finance
- Exchange
- DSGN Nasdaq
- RCS Nasdaq
- Market Cap
- DSGN 348.2M
- RCS 292.8M
- IPO Year
- DSGN 2021
- RCS N/A
- Fundamental
- Price
- DSGN $4.87
- RCS $6.54
- Analyst Decision
- DSGN Hold
- RCS
- Analyst Count
- DSGN 3
- RCS 0
- Target Price
- DSGN $7.00
- RCS N/A
- AVG Volume (30 Days)
- DSGN 220.6K
- RCS 141.1K
- Earning Date
- DSGN 03-18-2025
- RCS 01-01-0001
- Dividend Yield
- DSGN N/A
- RCS 10.12%
- EPS Growth
- DSGN N/A
- RCS N/A
- EPS
- DSGN N/A
- RCS N/A
- Revenue
- DSGN N/A
- RCS N/A
- Revenue This Year
- DSGN N/A
- RCS N/A
- Revenue Next Year
- DSGN N/A
- RCS N/A
- P/E Ratio
- DSGN N/A
- RCS N/A
- Revenue Growth
- DSGN N/A
- RCS N/A
- 52 Week Low
- DSGN $2.25
- RCS $4.51
- 52 Week High
- DSGN $7.77
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- DSGN 42.19
- RCS 41.39
- Support Level
- DSGN $3.71
- RCS $6.26
- Resistance Level
- DSGN $6.81
- RCS $6.50
- Average True Range (ATR)
- DSGN 0.50
- RCS 0.32
- MACD
- DSGN -0.10
- RCS 0.01
- Stochastic Oscillator
- DSGN 37.42
- RCS 41.35
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.